Infinium Global Research Biological Drugs Market | Page 2

A latest report has been added to the wide database of Biological Drug Market by Infinium Global Research. This report
studies the Diabetes Drug Therapy Market by Product Type (therapeutic protein -levemir, neulasta, eylea, novolog, enbrel,
avonex, neupogen, humalog, victoza, lantus, epogen, aranesp; monoclonal antibody - avastin, humira, remicade; vaccine -
gardasil, prenvar 13, fluzone) market status and outlook of global and major regions, from manufacturers, and end industries.
The objective of the study is to identify market sizes of different segments & countries in recent years and to forecast the
values for the next six years. Diabetes Drug Therapy Market provides opportunities in micro markets for stakeholders to
invest along with the detailed analysis of competitive landscape, latest trends, and product offerings of the major companies
in the Diabetes Drug Therapy Market. According to the report the Global Biological Drugs Market is projected to grow at a
CAGR between 10.0% to 10.5% in terms of value over the period of 2017-2023. Increasing geriatric population in the world is
driving the growth of the biological drugs market, as there is increasing requirement for effective medicines for various
illnesses affecting old age people. Increasing number of patients with cancer, diabetes and other major chronic illnesses are
expected to drive the growth of the biological drugs market during the forecast period. Biological drugs are more effective
than respective chemical and other alternative medicines for several complex chronic illnesses. Hence, the biological drugs
market is anticipated to attain significant growth in demand, despite the high cost of the products. The investments in
research and development of biological drugs and innovation in manufacturing of biologics are anticipated to yield more
products during the forecast period. Moreover, the promotional activities by various health organisations and policies by
governments to make biological drugs affordable for the treatment of chronic illnesses are expected to enhance the growth
of the global biological drugs market. Furthermore, the health regulatory policies with restrictions on chemical drugs with
severe side effects and the improving healthcare services in various countries are expected to enhance the growth of the
global biological drugs market.
The expiry of patents of many biological drugs provides opportunity for low cost biosimilars and other biological
pharmaceutical companies to manufacture alternative drugs. Higher cost of manufacturing and the higher selling price of
biological drugs give biosimilars and other alternatives the price advantage. Severe side effects related to injectable type of
biological drugs is a restraint to the expansion of the market. The complexity of manufacturing of biological drugs is a major
challenge for the global biological manufacturers, especially in the developing and least developed countries, where it is
difficult to maintain both the controlled environment for manufacturing and quality control. Moreover, lack of proper
refrigeration or environment controllable transportation facilities hinder the uniform quality of biological drugs in different
regions, due to contamination at different stages. However, the need for effective medicines for illnesses like cancer,
Infinium Global Research